Advertisement

Melatonergic Drug Ramelteon in Neurotherapeutics

  • Venkataramanujam Srinivasan
  • Rahimah Zakaria
  • Domenico de Berardis
  • Francisco López-Muñoz
  • Mohd Jamil Yaacob
  • Zahiruddin Othman
  • Amnon Brzezinski
Chapter

Abstract

Melatonin, the hormone secreted by the pineal gland, plays an important role in sleep induction and sleep maintenance. With the advancement of age, there is a decline in melatonin production, and elderly individuals often complain difficulties in sleep onset, maintenance of sleep-wake rhythm, and poor quality of sleep. Melatonin replacement therapy has been used for treating insomnias but it is not uniformly successful. With the synthesis of melatonergic agonist, ramelteon, a chronohypnotic drug with a higher affinity for MT1 and MT2 melatonergic receptors, treatment of insomnias has become easy, and many clinical studies have attested the efficacy of ramelteon in treating primary insomnia and secondary insomnias associated with neurodegenerative and neurodevelopmental disorders like autistic disorder. Melatonin has been implicated in the pathogenesis of delirium and autism spectrum disorders (ASD) and has been tried for treatment of these disorders. Although found successful in treating these disorders, melatonergic agonist ramelteon is used for treating autistic disorder and delirium where the drug has been found effective in not only alleviating the sleep disorders but also the behavioral problems. A low or abnormal level of melatonin is suggested as one of the main reasons for the lack of communication skill and socialization which are the main symptoms of ASD. Ramelteon has been used for treating rapid eye movement (REM) sleep behavior disorder (RBD) also and is found to be effective in increasing sleep efficiency and reducing the intensity of behavioral symptoms of this disorder. As a chronohypnotic drug, ramelteon ameliorated the symptoms of jet lag by improving the nighttime sleep efficiency and daytime alertness.

Keywords

Autism Spectrum Disorder Autistic Disorder NREM Sleep Autistic Spectrum Disorder Child Autism Spectrum Disorder Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Cajochen C. TAK-375 Takeda. Curr Opin Investig Drug. 2005;6:114–21.Google Scholar
  2. 2.
    Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48:301–10.CrossRefPubMedGoogle Scholar
  3. 3.
    Srinivasan V, Brzezinski A, Pandi-Perumal SR, Spence DW, Cardinali DP, Brown GM. Melatonin agonists in primary insomnia and depression associated insomnia: are they superior to sedative hypnotics. Progr Neuropsychopharmacol Biol Psychiatry. 2011;35(4):913–23.CrossRefGoogle Scholar
  4. 4.
    Srinivasan V, Zakaria R, Othman Z, Brzezinski A, Prasad A, Brown GM. Melatonergic drugs for therapeutic use in insomnia and sleep disturbances of mood disorders. CNS Neurol Disord Drug Ther. 2012;11:180–9.CrossRefGoogle Scholar
  5. 5.
    Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med. 2014;15:385–92.CrossRefPubMedGoogle Scholar
  6. 6.
    Nomura T, Kawase S, Watnabe Y, Nakashima K. Use of ramelteon for the treatment of secondary REM sleep behaviour disorder. Int Med. 2013;52:2123–6.CrossRefGoogle Scholar
  7. 7.
    Kawabe K, Horiuchi F, Oka Y, Shu-ichi Ueno. The melatonin receptor agonist ramelteon effectively treats insomnia and behavioural symptoms in autistic disorder. Case Rep Psychiatry 2014; Article ID 561071:5 p. http://dx.doi.org/10.1155/2014/561071.
  8. 8.
    Hatta K, Kishi Y, Takeuchi T, Odawara T, Usui C, Nakamura H, DELIRIA-J Group. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry. 2014;71(4):397–403.CrossRefPubMedGoogle Scholar
  9. 9.
    Imbesi M, Uz T, Dzitoyeva S, Manev H. Stimulatory effects of melatonin receptor agonist, ramelteon, on BDNF in mouse cerebellar granule cells. Neurosci Lett. 2008;439(1):34–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Greenblatt DJ, Harmatz JS, Karim A. Age and gender effects on the pharmacokinetics of ramelteon, a hypnotic drug acting via melatonin receptors MT1 and MT2. J Clin Pharmacol. 2007;47:485–96.CrossRefPubMedGoogle Scholar
  11. 11.
    Stevenson S, Bryson S, Amayke D, Hibberd M. Study to investigate the absolute bioavailability of a single overdose of ramelteon (TAK-375) in healthy male subjects. Clin Pharmacol Ther. 2004;75:22.Google Scholar
  12. 12.
    Nishiyama K, Nishikawa H, Kato K, Miyamoto M, Tsukamoto T, Hirai K. Pharmacological characterization of M-II, the major human metabolite of ramelteon. Pharmacology. 2014;93(3–4):197–201.CrossRefPubMedGoogle Scholar
  13. 13.
    Summers MO, Crisostomo MI, Stepanski EJ. Recent developments in the classification, evaluation, and treatment of insomnia. Chest. 2006;130:276–86.CrossRefPubMedGoogle Scholar
  14. 14.
    Crico M, Simonsick EM, Foley DJ. The impact of insomnia on cognitive functioning in older subjects. J Am Geriatr Soc. 2001;49:1185–9.CrossRefGoogle Scholar
  15. 15.
    Walsh JK. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry. 2004;65 Suppl 8:13–9.PubMedGoogle Scholar
  16. 16.
    Fuller PM, Gooley JJ, Saper CB. Neurobiology of the sleep-wake cycle: sleep architecture, circadian regulation and regulatory feedback. J Biol Rhythms. 2006;21:482–93.CrossRefPubMedGoogle Scholar
  17. 17.
    Wilson SJ, Nutt DJ, Alford C, Argyropoulos SV, Baldwin DS, Bateson AN, Britton TC, Crowe C, Dijk DJ, Espie CA, Gringras P, Hajak G, Idzikowski C, Krystal AD, Nash JR, Selsick H, Sharpley AL, Wade AG. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias, and circadian rhythm disorders. J Psychopharmacol. 2010;24:1577–601.CrossRefPubMedGoogle Scholar
  18. 18.
    Morin SK. Strategies for treating chronic insomnia. Am J Manag Care. 2006;12:S 230–45.Google Scholar
  19. 19.
    Montgomery P, Dennis J. A systematic review of non-pharmacological therapies for sleep problems in later life. Sleep Med Rev. 2004;8:47–62.CrossRefPubMedGoogle Scholar
  20. 20.
    Srinivasan V. The Pineal gland. Its physiological and pharmacological role. Ind J Physiol Pharmacol. 1989;33:263–72.Google Scholar
  21. 21.
    Haimov I, Laudon M, Zisapel N, Souroujon M, Nof D, Shiltner A, Herer P, Tzischinsky O, Lavie P. Sleep disorders and melatonin rhythms in elderly people. Br Med J. 1994;309:167.CrossRefGoogle Scholar
  22. 22.
    Rodenbeck A, Huether G, Hajak G. Altered circadian melatonin secretion patterns in relation to sleep in patients with chronic sleep-wake rhythm disorders. J Pineal Res. 1998;25:201–10.CrossRefPubMedGoogle Scholar
  23. 23.
    Leger D, Laudon M, Zisapel N. Nocturnal 6-sulphatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med. 2004;116:91–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Vohra S, Klassen TP, Baker G. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: a meta-analysis. BMJ. 2006;332:385–93.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Brezenski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005;9:41–50.CrossRefGoogle Scholar
  26. 26.
    Lyseng-Williamson KA. Melatonin prolonged release. Drug Aging. 2012;29(11):911–23.CrossRefGoogle Scholar
  27. 27.
    Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375) a selective MT1/MT2 receptor agonist reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005;28:303–7.PubMedGoogle Scholar
  28. 28.
    Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient reported latency in older adults with chronic insomnia. Sleep Med. 2006;7:312–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Erman M, Seiden D, Zammit G, Sainati S, Zhang J, Zee P. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med. 2006;7:17–24.CrossRefPubMedGoogle Scholar
  30. 30.
    Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-day period, crossover study of ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin. 2007;23:1005–14.CrossRefPubMedGoogle Scholar
  31. 31.
    Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007;3:495–504.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Mini L, Wang-Weigand S, Zhang J. Ramelteon 8 mg/day versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50 % or greater reduction in latency to persistent sleep as a measure of treatment effect. Clin Ther. 2008;30:1316–23.CrossRefPubMedGoogle Scholar
  33. 33.
    Dobkin RD, Menza M, Bienfait KL, Allen LA, Marin H, Gara MA. Ramelteon for the treatment of insomnia in menopausal women. Menopause Int. 2009;15:13–8.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Mayer G, Wang-Weigand S, Roth-Schechter B, Lehmann R, Staner C, Partonen M. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic insomnia. Sleep Med. 2009;32:351–60.Google Scholar
  35. 35.
    Goonerante NS, Gehrman P, Gurubhagavatula I, Al-Shehahi I, Marie L, Schwab R. Effectiveness of ramelteon for insomnia symptoms in older adults with obstructive sleep apnea: a randomized placebo-controlled pilot study. J Clin Sleep Med. 2010;6:572–80.Google Scholar
  36. 36.
    Uchimura N, Ogawa A, Hamamura M, Hashimoto T, Nagata H, Uchiyama M. Efficacy and safety of ramelteon in Japanese adults with chronic insomnia: a randomized double-blind placebo-controlled study. Expert Rev Neurother. 2011;11:215–24.CrossRefPubMedGoogle Scholar
  37. 37.
    Uchiyama M, Hamamura M, Kuwano T, Nagata H, Hashimoto T, Ogawa A, Uchimura N. Long-term safety and efficacy of ramelteon in Japanese patients with chronic insomnia. Sleep Med. 2011;12:127–33.CrossRefPubMedGoogle Scholar
  38. 38.
    Kohsaka M, Kanemura T, Taniguchi M, Kuwahara H, Mikami A, Kamikawa K, Uno H, Ogawa A, Murasaki M, Sugita Y. Efficacy and tolerability of ramelteon in a double-blind placebo-controlled crossover study in Japanese patients with chronic primary insomnia. Expert Rev Neurother. 2011;11:1389–97.CrossRefPubMedGoogle Scholar
  39. 39.
    Wang-Weigand S, Watissee M, Roth T. Use of a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia. Sleep Med. 2011;12:920–3.CrossRefPubMedGoogle Scholar
  40. 40.
    Kumar S, Bhattia M, Behari M. Sleep disorders in Parkinson’s disease. Mov Disord. 2002;17:775–81.CrossRefPubMedGoogle Scholar
  41. 41.
    Willis GI. Parkinson’s disease as a neuroendocrine disorder of the circadian function, dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process. Rev Neurosci. 2008;19:245–316.CrossRefPubMedGoogle Scholar
  42. 42.
    Boeve BF, Silber MH, Ferman TJ. Melatonin for the treatment of REM sleep behavior disorder in neurologic disorder; results in 14 patients. Sleep Med. 2003;4:281–4.CrossRefPubMedGoogle Scholar
  43. 43.
    Rocchitta G, Migheli R, Esposito G, Marchetti B, Desole MS, Miele E, Serra PA. Endogenous melatonin protects L-DOPA from auto-oxidation in the striatal extracellular component of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinson’s disease. J Pineal Res. 2006;40:204–13.CrossRefPubMedGoogle Scholar
  44. 44.
    Mc Carter SJ, Louis EK, Boeve BF. REM sleep behavior disorder and REM sleep without atonia as an early manifestation of degenerative neurological disease. Curr Neurol Neurosci Rep. 2012;12:182–92.CrossRefGoogle Scholar
  45. 45.
    Richardson GS, Zee P, Wang-Weigand S, Rodriguez L, Peng X. Circadian phase shifting effects of repeated ramelteon administration in healthy adults. J Clin Sleep Med. 2008;4:456–61.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Waterhouse J, Reilly T, Atkinson C. Jet lag. Lancet. 1997;350:1611–6.CrossRefPubMedGoogle Scholar
  47. 47.
    Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, Reppert SM. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. 1997;19:91–102.CrossRefPubMedGoogle Scholar
  48. 48.
    Zee PC, Wang-Weigand S, Wright Jr KP, Peng X, Roth T. Effects of ramelteon on insomnia symptoms induced by rapid eastward travel. Sleep Med. 2010;11:S25–33.CrossRefGoogle Scholar
  49. 49.
    Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009;15:32–51.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Saper CB, Lu J, Chou TC, Gooley J. The hypothalamic integrator for circadian rhythms. Trends NeuroSci. 2005;28:152–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Comai S, Ochoa-Sanchez R, Gobbi G. Sleep-wake characterization of double MT1/MT2 receptor knockout mice and comparison with MT1and MT2 receptor knockout mice. Behav Brain Res. 2013;243:231–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Dubocovich ML. Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Med. 2007;8:34–42.CrossRefPubMedGoogle Scholar
  53. 53.
    Comai S, Gobbi S. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. J Psychiatry Neurosci. 2014;39(1):6–21.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Rivara S, Lodola A, Mor M, Bedini A, Spadoni G, Lucini V, Pannacci M, Fraschini F, Scaglione F, Sanchez RO, Gobbi G, Tarzia G. N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. J Med Chem. 2007;50:6618–26.CrossRefPubMedGoogle Scholar
  55. 55.
    Faust R, Garratt PJ, Jones R, Yeh LK, Tsotinis A, Panoussopoulou M, Calogeropoulou T, Teh MT, Sugden D. Mapping the melatonin receptor 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles. J Med Chem. 2000;43:1050–61.CrossRefPubMedGoogle Scholar
  56. 56.
    Sampson EL, Raven PR, Ndhlovu PN, Vallance A, Garlick N, Watts J, Blanchard MR, Bruce A, Blizard R, Ritchie CW. A randomized, double blind, placebo-controlled trial of donepezil hydrochloride (Aricept) for reducing the incidence of postoperative delirium after elective total hip replacement. Int J Geriatr Psychiatry. 2007;22(4):343–9.CrossRefPubMedGoogle Scholar
  57. 57.
    Elie M, Cole MG, Primeau FJ, Bellavance F. Delirium risk factors in elderly hospitalized patients. J Gen Intern Med. 1998;13(3):204–12.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Al-Aama T, Brymer C, Gutmanis I, Woolmore-Goodwin SM, Esbaugh J, Dasgupta M. Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial. Int J Geriatr Psychiatry. 2011;26:687–94.CrossRefPubMedGoogle Scholar
  59. 59.
    Gunther ML, Morandi A, Ely EW. Pathophysiology of delirium in the intensive care unit. Crit Care Clin. 2008;24:45–65.CrossRefPubMedGoogle Scholar
  60. 60.
    Hshieh TT, Fong TG, Marcantonio ER, Inouye SK. Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence. J Gerontol A Biol Sci Med Sci. 2008;63:764–72.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Van Munster BC, Korevaar JC, Zwinderma AH, Levi M, Wiersinga WJ, De Rooij SE. Time course of cytokines during delirium in elderly patients with hip fractures. J Am Geriatr Soc. 2008;56:1704–9.CrossRefPubMedGoogle Scholar
  62. 62.
    Iguchi H, Kato K, Ibayashi H. Age-dependent reduction in serum melatonin concentration in healthy human subjects. J Clin Endocrinol Metab. 1982;55:27–9.CrossRefGoogle Scholar
  63. 63.
    Furuya M, Miyaoka T, Yasuda H, Yamashita S, Tanaka I, Otsuka S, Wake R, Horiguchi J. Marked improvement in delirium with ramelteon: five case reports. Psychogeriatrics. 2012;12:259–62.CrossRefPubMedGoogle Scholar
  64. 64.
    Marcantonio ER, Rudolph GL, Culley D, Crosby G, Alsop D, Inouye SK. Serum biomarkers for delirium. J Gerontol Biol Sci Med Sci. 2006;61A:1281–6.CrossRefGoogle Scholar
  65. 65.
    Balan S, Leibovitz A, Zila SO, et al. The relation between clinical subtypes of delirium and the urinary levels of 6-SMT. J Neuropsychiatr Clin Neurosci. 2003;5:363–6.CrossRefGoogle Scholar
  66. 66.
    Lewis M, Barnett S. Postoperative delirium; the tryptophan dysregulation model. Med Hypotheses. 2004;63:402–6.CrossRefPubMedGoogle Scholar
  67. 67.
    Kalisvaar KJ, De Jonghe JF, Bogaards MJ, Vreeswijk R, Egberts TC, Burger BJ, Eikelenboom P, van Gool WA. Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study. J Am Geriatr Soc. 2005;53(10):1658–66.CrossRefGoogle Scholar
  68. 68.
    Liptizin B, Laki A, Garb JL, Fingeroth R, Krushell R. Donepezil in the prevention and treatment of post-surgical delirium. Am J Geriar Psychiatr. 2005;13(12):1100–6.CrossRefGoogle Scholar
  69. 69.
    Kimura R, Mori K, Kumazaki H, Yanagida M, Taguchi S, Matsunaga H. Treatment of delirium with ramelteon: initial experience in three patients. Gen Hospital Psych. 2011;33:407–9.CrossRefGoogle Scholar
  70. 70.
    Ohta T, Murao K, Miyake K, Takemoto K. Melatonin receptor agonists for treating delirium in elderly patients with acute stroke. J Stroke Cerebrovasc Dis. 2013;7:1107–10.CrossRefGoogle Scholar
  71. 71.
    Volkmar FR, Klin A, Siegal B, Szatmari P, Lord C, Campbell M, Freeman BJ, Cicchetti DV, Rutter M, Kline W, et al. Field trial for autistic disorder in DSM-IV. Am J Psychiatry. 1994;15(9):1361–7.Google Scholar
  72. 72.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn. Text Revision. Washington DC: American Psychiatric Association; 2000.Google Scholar
  73. 73.
    Bauman ML, Kemper TL. Neuroanatomic observation of the brain in autism: a review and future direction. Int J Dev Neurosci. 2005;23(2–3):183–7.CrossRefPubMedGoogle Scholar
  74. 74.
    Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo C. Neurological activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57(1):67–81.CrossRefPubMedGoogle Scholar
  75. 75.
    MacFabe DF, Cain DP, Rodriguez-Capote K, Franklin AE, Hoffman JE, Boon F, Taylor AR, Kavaliers M, Ossenkopp KP. Neurobiological effects of intraventricular propionic acid in rats. Possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders. Behav Brain Res. 2007;176(1):149–69.CrossRefPubMedGoogle Scholar
  76. 76.
    Shultz SR, MacFabe DF, Osenkopp K, Scratch S, Whelan J, Taylor R, Cain DP. Intracerebroventricular injection of propionic acid, an enteric bacterial metabolic end-product impairs social behavior in the rat: implications for an animal model of autism. Neuropharmacology. 2008;54(6):901–11.CrossRefPubMedGoogle Scholar
  77. 77.
    Hu VW, Nguyen AT, Soon Kim K, Steinberg ME, Sarachana T, Scully MA, Soldin SJ, Luu T, Lee NH. Gene expression profiling of lymphoblasts from autistic and nonaffected sib pairs: altered pathways in neuronal development and steroid biosynthesis. PLoS One. 2009;4(6):e5775.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Hu VW, Sarachana T, Kim KS, Nquyen A, Kulkarni S, Steinberg ME, Luu T, Lai Y, Lee NH. Gene expression profiling differentiates autism case controls and phenotype variants of autism spectrum disorders: evidence for circadian rhythm dysfunction in severe autism. Autism Res. 2009;2(2):78–97.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Thomas NS, Sharp AJ, Browne CE, Skuse D, Harde C, Dennis NR. Xp deletions associated with autism in three females. Hum Genet. 1999;104:43–8.CrossRefPubMedGoogle Scholar
  80. 80.
    Yi H, Donohue HJ, Klein DC, McBride OW. Localization of the hydroxyindole-O-methyltransferase gene to the pseudoautosomal region: implications for mapping of psychiatric disorders. Hum Mol Genet. 1993;2:127–31.CrossRefPubMedGoogle Scholar
  81. 81.
    Veatch OJ, Pendergast JS, Allen MJ, Leu RM, Johnson CH, Elsea SH, Malow BA. Genetic variation in melatonin pathway enzymes in children with autism spectrum disorder and comorbid sleep onset delay. J Autism Dev Disord. 2014;45(1):100–10.CrossRefGoogle Scholar
  82. 82.
    Nir I, Meir D, Zilber N, Knobler H, Hadjez J, Lerner Y. Brief report: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord. 1995;25:641–54.CrossRefPubMedGoogle Scholar
  83. 83.
    Kulman G, Lissoni P, Rovelli F, Roselli MG, Brivio F, Sequeri P. Evidence of pineal endocrine hypofunction in autistic children. Neuroendocrinol Lett. 2000;21:31–4.PubMedGoogle Scholar
  84. 84.
    Tordjman S, Anderson GM, Pichard N, Charbuy H, Touitou Y. Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder. Biol Psychiatry. 2005;57:134–8.CrossRefPubMedGoogle Scholar
  85. 85.
    Melke J, Goubran Botros H, Chaste P, Betancur C, Nygren G, Anckarsäter H, Rastam M, Ståhlberg O, Gillberg IC, Delorme R, Chabane N, Mouren-Simeoni MC, Fauchereau F, Durand CM, Chevalier F, Drouot X, Collet C, Launay JM, Leboyer M, Gillberg C, Bourgeron T. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry. 2008;13(1):90–8.CrossRefPubMedGoogle Scholar
  86. 86.
    Smith AG, Dykens A, Greenberg F. Behavioural phenotypes of Smith-Magenis syndrome (del 17p11.2). Am J Med Genet. 1998;81:179–85.CrossRefPubMedGoogle Scholar
  87. 87.
    Johnson KP, Sikora DM. Autism spectrum disorders and sleep. In: Ivanenko A, editor. Sleep and psychiatric disorders in children and adolescents. New York: Informa Health Care; 2008. p. 329–38.Google Scholar
  88. 88.
    Tordjman S, Najjar I, Bellissant E, Anderson GM, Barburoth M, Cohen D, Jaafari N, Schischmanoff O, Fagard R, Lagdas E, Kermarrec S, Ribardiere S, Botbol M, Fougerou C, Bronsard G, Vernay-Leconte J. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci. 2013;14:20508–42.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Henderson JA, Barry TD, Bader SH, Jordan SS. The relation among sleep routines and externalizing behavior in children with an autism spectrum disorder. Res Aut Spectr Dis. 2002;32:553–61.Google Scholar
  90. 90.
    Richdale A, Prior MR. The sleep/wake rhythm in children with autism. Eur Child Adolesc Psychiatry. 1995;4:4–15.CrossRefGoogle Scholar
  91. 91.
    Wiggs L, Stores G. Sleep patterns and sleep disorders in children with autistic spectrum disorders: insights using parental report and actigraphy. Dev Med Child Neurol. 2004;46:372–80.CrossRefPubMedGoogle Scholar
  92. 92.
    Limoges E, Mottron L, Bolduc C, Godbout R. Atypical sleep architecture and the autism phenotypes. Brain. 2005;128(Part 5):1049–61.CrossRefPubMedGoogle Scholar
  93. 93.
    Hayashi E. Effect of melatonin on sleep-wake rhythm: the sleep diary of an autistic male. Psychiatry Clin NeuroSci. 2000;54:383–4.CrossRefPubMedGoogle Scholar
  94. 94.
    Couturier JL, Speechley KN, Steele M, Norman R, Stringer B, Nicolson R. Parental perception of sleep problems in children of normal intelligence with pervasive developmental disorders. Prevalence, severity, and pattern. J Am Acad Child Adolesc Psychiatry. 2005;44(8):815–22.CrossRefPubMedGoogle Scholar
  95. 95.
    Polimeni MA, Richdale AL, Francis AJP. A survey of sleep problems in autism, Asperger’s disorder, and typically developing children. J Intellect Disab Res. 2005;49(4):260–8.CrossRefGoogle Scholar
  96. 96.
    Malow BA, McGrew SG. Sleep interventions in children with autism spectrum disorders. In: Ivanenko A, editor. Sleep and psychiatric disorders in children and adolescents. New York: Informa Health Care; 2008. p. 339–49.Google Scholar
  97. 97.
    Ross C, Davies P, Whitehouse W. Melatonin treatment for sleep disorders in children with neurodevelopmental disorders: an observational study. Dev Med Child Neurol. 2004;44:339–44.CrossRefGoogle Scholar
  98. 98.
    Phillips L, Appleton R. Systematic review of melatonin treatment in children with neurodevelopmental disabilities and sleep impairment. Dev Med Child Neurol. 2004;46:771–5.CrossRefPubMedGoogle Scholar
  99. 99.
    Dodge NN, Wilson GA. Melatonin for treatment of sleep disorders in children with developmental disabilities. J Child Neurol. 2001;16:581–4.CrossRefPubMedGoogle Scholar
  100. 100.
    Anderson I, Kaczmarska J, McGrew SG, Malow BA. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol. 2008;23:482–5.CrossRefGoogle Scholar
  101. 101.
    Paavonen EJ, Nieminen-von Wendt T, Vanhala R, Aronen ET, von Wendt L. Effectiveness of melatonin in the treatment of sleep disturbances in children with Asperger disorder. J Child Adolesc Psychopharmacol. 2003;13:83–95.CrossRefPubMedGoogle Scholar
  102. 102.
    Cortesi F, Giannotti F, Sebastini T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res. 2012;21:700–9.CrossRefPubMedGoogle Scholar
  103. 103.
    Malow B, Adkins KW, McGrew SG, Wang L, Goldman SE, Fawkes D, Burnette C. Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord. 2012;42:1729–37.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Stigler KA, Posey DJ, McDougle CJ. Ramelteon for insomnia in two youths with autistic disorder. J Child Adolesc Psychopharmacol. 2006;16(5):631–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  • Venkataramanujam Srinivasan
    • 1
  • Rahimah Zakaria
    • 2
  • Domenico de Berardis
    • 3
    • 4
  • Francisco López-Muñoz
    • 5
    • 6
    • 7
  • Mohd Jamil Yaacob
    • 8
  • Zahiruddin Othman
    • 9
  • Amnon Brzezinski
    • 10
  1. 1.Sri Sathya Sai Medical Educational and Research FoundationInternational Medical Sciences Research Study Center Prasanthi NilayamKovai CoimbatoreIndia
  2. 2.Department of Physiology School of Medical SciencesUniversiti Sains MalaysiaKubang KerianMalaysia
  3. 3.NHS, Department of Mental HealthPsychiatry Service of Diagnosis and Treatment Hospital “G.Mazzini”TeramoItaly
  4. 4.Department of Neurosciences and Imaging and Clinical SciencesUniversity “G.D Annunzio”ChietyItaly
  5. 5.Faculty of Health SciencesCamilo José Cela UniversityMadridSpain
  6. 6.Neuropsychopharmacology UnitHospital 12 de Octubre Research Institute (i+12)MadridSpain
  7. 7.Portucalense Institute of Neuropsychology and Cognitive and Behavioural NeurosciencesPortucalense UniversityPortoPortugal
  8. 8.Department of Psychiatry, Faculty of MedicineAsian Institute of Medicine, Science and TechnologyBedongMalaysia
  9. 9.Department of PsychiatrySchool of Medical Sciences Universiti Sains MalaysiaKubang KerianMalaysia
  10. 10.Department of Obstetrics and Gynecology, Haddasah Medical CenterThe Hebrew UniversityJerusalemIsrael

Personalised recommendations